Skip to content

Effect of Vitamin D3 on Vascular Function

The Effect of Cholecalciferol (Vitamin D3) on Vascular Function and Cardiovascular Risk Factors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00948298
Enrollment
130
Registered
2009-07-29
Start date
2009-07-31
Completion date
2012-08-31
Last updated
2018-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D Deficiency

Keywords

cardiovascular disease, vitamin D, african american, low vitamin D levels

Brief summary

Vitamin D is a natural nutrient. A little comes from our normal daily diet. Most of it comes from our skin after we have been in sunlight. If we have darker skin, we make less vitamin D. Vitamin D balances the calcium in our body. If our vitamin D levels get too low, it can cause health problems. It may increase our chance of getting high blood pressure or diabetes. Another problem we may have if our vitamin D levels are low is that our blood vessels may not work normally. These are important health problems for anyone. Because African Americans have darker skin, they are more likely than most other racial/ethnic groups to have low vitamin D levels. This study will look at treating African Americans with low vitamin D levels. The goal of this study is to see how vitamin D helps blood vessels work. The investigators will do this study in African Americans who are overweight, have high blood pressure and have low vitamin D levels. The investigators will see if getting the vitamin D level to a normal value will improve how blood vessels work. The dose of vitamin D that will be given in this study is a high dose that is given to people with low vitamin D levels.

Detailed description

Cardiovascular Disease (CVD) and related disorders remain the leading cause of death in the nation. Hypovitaminosis D has been linked not only to several cardiovascular (CV) risk factors including hypertension, diabetes, obesity but also to increased rates of CVD. Thus,hypovitaminosis D presents a common pathway for a select subgroup with a clustering of CV risk factors in a profile that is predominant among ethnic minorities. Indeed, hypovitaminosis D is highly prevalent with an estimated 55% of the US adult population having levels at or below 30 ng/ml, and over 80% of African Americans having suboptimal values. Thus, we propose a twelve week randomized double-blind, placebo controlled pilot trial to assess the effect on vascular function and CV risk factors of 100,000 IU Vitamin D3 given every 4 weeks to overweight, hypertensive African-Americans with hypovitaminosis D. To our knowledge, the proposed project is the first to assess the effect of 'high-dose' Vitamin D3 administration on vascular function.We believe this study is also the first to examine the impact at a molecular level of Vitamin D3 repletion on the key mediators of cardio-metabolic pathways in humans. If our study results support our working hypothesis, we will be positioned to propose a larger scale study to detect a therapeutic effect on more definitive, clinical cardiovascular endpoints across a more diverse population. Objectives: 1\. Assess the role of Vitamin D3 treatment on vascular function in high risk subjects. Primary Outcome: The primary outcome variable is pulse wave velocity (PWV, unit - m/s) for vascular stiffness assessed by radial artery tonometry (via SphygmoCor). The hypothesis for the primary analysis is that a greater increase in the PWV will occur in the Vitamin D3 treatment group than in the placebo group. Secondary Outcome: Vascular/endothelial function as determined by measuring non-invasive vascular finger plethysmography (via EndoPat). Additional surrogates to be assessed as secondary markers of vascular/endothelial function include sitting and 24 hour ambulatory blood pressure measurements and spot urine protein/creatinine ratio.

Interventions

DRUGVitamin D

Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.

DRUGPlacebo

Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.

Sponsors

National Center for Research Resources (NCRR)
CollaboratorNIH
Charles Drew University of Medicine and Science
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Males or females, 18-70 years of age and self-identified as African-American or Black * Hypertension * If a potential study patient is not on treatment, their systolic blood pressure (SBP) must be \> 130 mmHg, or diastolic blood pressure (DBP) \> 85 mmHg, and SBP must be \<160 mmHg and DBP must be \< 105 mmHg. * If a potential study patient is on treatment then the SBP must be \<160 mmHg and DBP must be \< 105 mmHg * Screening Vitamin D (D2 and D3 level) between 10 and 25 ng/ml (normal level \> 30 ng/ml) * Body mass index (BMI) \> 25 kg/m2

Exclusion criteria

* Poorly controlled high blood pressure (SBP \>160 mmHg or DBP \> 105 mmHg) * Diabetes (fasting blood sugar \> 125 mg/dl, or HbA1c \> 6.5%) * Screening Vitamin D (D2 and D3 level) \< 10 ng/ml or \> 25 ng/ml * Estimated glomerular filtration rate (eGFR) \< 45 ml/min * Evidence of disease resulting in hypercalcemia * History of kidney stones * History of drug, alcohol, or illicit substance abuse within the past 6 months * History of another chronic disease which the investigator feels should preclude the subject from entering the study * Liver function tests (LFTs) greater than twice the upper limit of normal * Subjects requiring chronic use of nonsteroidal anti-inflammatory drugs, aspirin, or other drugs that may affect the measurement of reactive oxidative species * Subjects requiring treatment with other vitamin D preparations containing more than 400 IU of vitamin D * Subjects requiring chronic use of immunosuppressive therapy or corticosteroids * Recent (\< 6 months) myocardial infarction, stroke, or hospitalization for congestive heart failure * Allergy/intolerance: known allergy to oral vitamin D or microcrystalline cellulose

Design outcomes

Primary

MeasureTime frameDescription
Pulse Wave Velocity for Vascular Stiffness12 WeeksThe primary outcome variable is pulse wave velocity (PWV) for vascular stiffness. The hypothesis is that a greater decrease in the PWV will occur with the Vitamin D3 treatment. PWV is the speed at which the arterial pulse wave travels through the arteries in the cardiovascular system. It is considered the gold standard for the assessment of arterial elastance (stiffness) and determined by radial artery applanation tonometry using the SphygmoCor device.

Secondary

MeasureTime frameDescription
Changes in Sitting and 24 Ambulatory Blood Pressure12 weeksImproved vascular function as determined by measuring sitting and 24 Hour Ambulatory Blood Pressure.

Participant flow

Participants by arm

ArmCount
Placebo
Placebo: Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
65
Vitamin D
Vitamin D: Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
65
Total130

Baseline characteristics

CharacteristicVitamin DPlaceboTotal
Age, Customized
18-39 years
10 Participants10 Participants20 Participants
Age, Customized
40-59 years
45 Participants47 Participants92 Participants
Age, Customized
60 years and above
10 Participants8 Participants18 Participants
Augmentation Index28.2 percentage of central pulse pressure
STANDARD_DEVIATION 11.2
31.0 percentage of central pulse pressure
STANDARD_DEVIATION 12
29.6 percentage of central pulse pressure
STANDARD_DEVIATION 11.6
Blood Pressure (Diastolic)80.9 mmHg
STANDARD_DEVIATION 11.4
84.5 mmHg
STANDARD_DEVIATION 10.5
82.7 mmHg
STANDARD_DEVIATION 11.1
Blood Pressure (Systolic)125.2 mmHg
STANDARD_DEVIATION 16.1
128.5 mmHg
STANDARD_DEVIATION 15.2
126.8 mmHg
STANDARD_DEVIATION 15.7
Body Mass Index, Categorical
25.0-29.9 kg/m^2
12 Participants18 Participants30 Participants
Body Mass Index, Categorical
>30 kg/m^2
53 Participants47 Participants100 Participants
Intact Parathyroid Hormone (PTH) Level43.4 pmol/L
STANDARD_DEVIATION 19.9
49.9 pmol/L
STANDARD_DEVIATION 33.6
46.7 pmol/L
STANDARD_DEVIATION 27.7
Region of Enrollment
United States
65 Participants65 Participants130 Participants
Serum 25(OH)D Level17.0 nmol/L
STANDARD_DEVIATION 5.2
16.5 nmol/L
STANDARD_DEVIATION 5
16.8 nmol/L
STANDARD_DEVIATION 5.1
Serum Calcium Level9.4 mg/dl
STANDARD_DEVIATION 0.3
9.3 mg/dl
STANDARD_DEVIATION 0.4
9.4 mg/dl
STANDARD_DEVIATION 0.4
Sex: Female, Male
Female
24 Participants27 Participants51 Participants
Sex: Female, Male
Male
41 Participants38 Participants79 Participants
Urine Isoprostane14.4 ng/mg
STANDARD_DEVIATION 11.6
14.9 ng/mg
STANDARD_DEVIATION 15.8
14.6 ng/mg
STANDARD_DEVIATION 13.8
Waist Circumference Groups
High (>=102 cm for male and >=88 cm for female)
53 Participants48 Participants101 Participants
Waist Circumference Groups
Low (<102 cm for male and <88 cm for female)
12 Participants17 Participants29 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 650 / 65
other
Total, other adverse events
12 / 6514 / 65
serious
Total, serious adverse events
4 / 654 / 65

Outcome results

Primary

Pulse Wave Velocity for Vascular Stiffness

The primary outcome variable is pulse wave velocity (PWV) for vascular stiffness. The hypothesis is that a greater decrease in the PWV will occur with the Vitamin D3 treatment. PWV is the speed at which the arterial pulse wave travels through the arteries in the cardiovascular system. It is considered the gold standard for the assessment of arterial elastance (stiffness) and determined by radial artery applanation tonometry using the SphygmoCor device.

Time frame: 12 Weeks

ArmMeasureValue (MEAN)Dispersion
PlaceboPulse Wave Velocity for Vascular Stiffness29.3 m/sStandard Deviation 11
Vitamin DPulse Wave Velocity for Vascular Stiffness27.6 m/sStandard Deviation 11
Secondary

Changes in Sitting and 24 Ambulatory Blood Pressure

Improved vascular function as determined by measuring sitting and 24 Hour Ambulatory Blood Pressure.

Time frame: 12 weeks

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboChanges in Sitting and 24 Ambulatory Blood Pressure24 Hour Blood Pressure (Systolic)128.4 mmHgStandard Deviation 14
PlaceboChanges in Sitting and 24 Ambulatory Blood PressureBlood Pressure (Systolic)125.8 mmHgStandard Deviation 13.3
PlaceboChanges in Sitting and 24 Ambulatory Blood Pressure24 Hour Blood Pressure (Diastolic)83.9 mmHgStandard Deviation 10.1
PlaceboChanges in Sitting and 24 Ambulatory Blood PressureBlood Pressure (Diastolic)82.2 mmHgStandard Deviation 9.2
Vitamin DChanges in Sitting and 24 Ambulatory Blood Pressure24 Hour Blood Pressure (Diastolic)82.0 mmHgStandard Deviation 11.6
Vitamin DChanges in Sitting and 24 Ambulatory Blood PressureBlood Pressure (Systolic)126.9 mmHgStandard Deviation 15
Vitamin DChanges in Sitting and 24 Ambulatory Blood Pressure24 Hour Blood Pressure (Systolic)127.4 mmHgStandard Deviation 16.4
Vitamin DChanges in Sitting and 24 Ambulatory Blood PressureBlood Pressure (Diastolic)81.1 mmHgStandard Deviation 12

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026